Abstract
Common statistical modeling methods do not necessarily produce the most relevant or interpretable effect estimates to communicate risk. Overreliance on the odds ratio and relative effect measures limit the potential impact of epidemiologic and public health research. We created a straightforward R package, called riskCommunicator, to facilitate the presentation of a variety of effect measures, including risk differences and ratios, number needed to treat, incidence rate differences and ratios, and mean differences. The riskCommunicator package uses g-computation with parametric regression models and bootstrapping for confidence intervals to estimate effect measures in time-fixed data. We demonstrate the utility of the package using data from the Framingham Heart Study to estimate the effect of prevalent diabetes on the 24-year risk of cardiovascular disease or death.
The absolute 24-year risk of cardiovascular disease or death was 30% (95% confidence interval (CI): 22, 38) higher among subjects with diabetes compared to subjects without diabetes at baseline. The relative 24-year risk was 55% (95% CI: 40, 70) higher. Because the outcome was common (41.8%), the odds ratio (4.55) is highly inflated compared to the risk ratio (1.55). An expected 4 additional persons would need to have diabetes at baseline to observe an increase in the number of cases of cardiovascular disease or death by 1 over 24 years of follow-up.
The package promotes the communication of public-health relevant effects and is accessible to a broad range of epidemiologists and health researchers with little to no expertise in causal inference methods or advanced coding.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (grant K01AI130326 to ETRM https://www.niaid.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Emory University IRB (not human subjects research)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
The package can be downloaded from the Comprehensive R Archive Network (CRAN) version 1.0.0 at https://CRAN.R-project.org/package=riskCommunicator. A development version, issue logging, and support can be found at https://github.com/jgrembi/riskCommunicator. The package includes two vignettes, one included as Supporting Information along with this manuscript and another targeted for new R users with additional details which can be downloaded from CRAN. The dataset (?framingham?) included in the package is from The Framingham Heart Study and it?s use for the purpose of this package was approved on 11 March 2019 (request #7161) by the National Institutes of Health/National Heart, Lung, and Blood Institute. This is a teaching dataset and specific methods were employed to ensure an anonymous dataset that protects patient confidentiality.
